The impact of the pharmaceutical pricing system on cost-effectiveness results: Finnish analysis

Open Pharmacoeconomics and Health Economics Journal

Volumn 3, Issue , 2011, Pages 6-10

  Hallinen, Taru ^a   Soini, Erkki J ^a  

^a Esior Oy   (Finland)

Author keywords

Cost utility; Finland; Incentives; Pharmaceuticals; Price regulation; Reimbursement

Indexed keywords

AGOMELATINE; CITALOPRAM; ETANERCEPT; EXENDIN 4; METFORMIN; METHOTREXATE; ROSUVASTATIN; SIMVASTATIN;

ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; DRUG DELIVERY SYSTEM; DRUG MARKETING; ECONOMIC EVALUATION; FINLAND; HEALTH ECONOMICS; INCREMENTAL COST EFFECTIVENESS RATIO; PHARMACEUTICAL PRICING SCHEME; PRIORITY JOURNAL; REIMBURSEMENT;

EID: 84855508204     PISSN: None     EISSN: 18768245     Source Type: Journal    
DOI: 10.2174/1876824501103010006     Document Type: Article

References (20)

1. Teperi J, Porter ME, Vuorenkoski L, Baron JF. The Finnish health care system: a value-based perspective. Helsinki: Sitra reports 82, 2009.
2. Häkkinen U. The impact of changes in Finland's health care system. Health Econ 2005; 14(Suppl 1): S101-18.
3. OECD Reviews of Health Systems: Finland. OECD, 2005.
4. Hermanson T, Aro S, Bennett CL. Finland's health care system. Universal access to health care in a capitalistic democracy. J Am Med Assoc 1994; 271: 1957-62.
5. Kivioja A. Lääketaloudellisen arvioinnin rooli lääkkeiden tukkuhinta- ja korvattavuuspäätöksissä (The role of pharmacoeconomic evaluations in the whole sale price and reimbursement decisions). Dosis 2006; 22: 301-7.
6. Ohje terveystaloudellisen selvityksen laatimiseksi (Guidelines for preparing a health economic evaluation). Appendix to the decree 201/2009 by the Ministry of Social Affairs and Health, Finland.
7. Pharmacoeconomic Guidelines around the World. Lawrenceville: ISPOR, 2011. Available [accessed 3rd April 2011]: http://www.ispo r.org/PEguidelines/index.asp
8. Soini EJ, Kukkonen J, Myllykangas M, Ryynänen OP. What is politician's and clinician's willingness to pay (WTP) for future health benefit based on 15D, EQ-5D and life-years? A contingent valuation (CV) among 8 diseases with the total of 1092 cases. In: Abstracts of the ISPOR (International Society for Pharmacoeconomics and Outcomes Research) Eleventh Annual European Congress. November 8-11 2008, Athens, Greece. Value Health 2008; 11: A556.
9. Lääkekorvaukset pienenivät 19 miljoonaa euroa (Drug reimbursements decreased by 19 million Euros) [Announcement on the internet]. Kela tiedottaa 2011; 4.3 [cited 3rd April 2011]. Available from: http://www.kela.fi/in/internet/suomi.nsf/NET/040 311101609PM?OpenDocument
10. Salokannel M, Hjelt P, Höykinpuro R, Lapiolahti S, Lindberg J, Vuorinen J. The impact of public health issues on exclusive patent rights [Report on the internet]. AIPPI report Q202 [cited 20th October 2011]. Available from: https://www.aippi.org/download/ commitees/202/GR202finland.pdf
11. Saarni SI, Härkänen T, Sintonen H, et al. The impact of 29 chronic conditions on health-related quality of life: a general population survey in Finland using 15D and EQ-5D. Qual Life Res 2006; 15: 1403-14.
12. Hallinen TA, Soini EJ, Eklund K, Puolakka K. Cost-utility of different treatment strategies after the failure of tumour necrosis factor inhibitor in rheumatoid arthritis in the Finnish setting. Rheumatology (Oxford) 2010; 49: 767-77.
13. Soini EJ, Hallinen TA, Kauppi MJ, Vihervaara V, Puolakka K. Comprehensive health economic assessment of sequenced treatment with biologics in moderate-to-severe rheumatoid arthritis: Analysis based on ACR50 and ACR70 responses. In: Abstracts of the American College of Rheumatology/Association of Rheumatology Health Professionals Annual Scientific Meeting Atlanta, Georgia November 6-11, 2010. Arthritis Rheum 2010; 62(Suppl 10): 759.
14. Soini EJ, Hallinen TA. Health economic study using survey data and modelling: Agomelatine, generic venlafaxine and placebo in the treatment of major depressive disorder. In the abstract book of 8th European Conference on Health Economics, Helsinki, Finland, July 7-10, 2010 [cited 3rd April 2011]. Available from: http://eche2010.abstractbook.org/presentations/254/
15. Soini EJ, Stevenson MD, Martikainen JA, Akehurst RL. Costutility of bosentan in the first-line treatment of pulmonary arterial hypertension in Finland - A discrete event simulation modelling. In: ISPOR (International Society for Pharmacoeconomics and Outcomes Research) 12th Annual European Congress, October 24-27, 2009, Paris, France. Value Health 2009; 12: A335.
16. Soini EJ, García San Andrés B, Joensuu T. Trabectedin in the treatment of metastatic soft tissue sarcoma: cost-effectiveness, costutility and value of information. Ann Oncol 2011; 22: 215-23.
17. Harjula I. Ovatko yrittäjän työkalut apteekkarin käytössä? (Can the conventional business tools be employed by pharmacy owners?) In: Lääkepäivät, 2008, Kuopio.
18. Martikainen J, Kivi I, Linnosmaa I. European prices of newly launched reimbursable pharmaceuticals - a pilot study. Health Policy 2005; 74: 235-46.
19. Fimea. Valtioneuvoston asetus lääketaksasta ja sairausvakuutuslain mukainen lääkekulujen vuotuinen potilaskohtainen omavastuu (Finnish government's decree on pharmaceutical fees and the annual patient deductible for pharmaceuticals according to Sickness Insurance Act). Muistio 6.7.2011. [Cited 19th August 2011]. Available from: http://www.fimea.fi/instancedata/prime_p roduct_j ulkaisu/fimea/embeds/fimeawwwstructure/18688_Fimea n_ehdotus_laaketaksa_ja_vuotuinen_laakekulujen_omavastuu_6_7_2011.pdf
20. Soini E. Harvinaissairauksien taloudellinen arviointi: mitä päätöksien tueksi tulisi tuottaa? (Health economic assessment of orphan diseases: what kind of information should be produced to support decision making?) Harvinaiset Sairaudet -lehti 2011; 1:26-31.